DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Drenth JPH, Schattenberg JM.
The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success.
Expert Opin Investig Drugs 2020;
29 (12) 1365-1375
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.